Cardiac Uptake of Metformin, Visualized by Positron Emission Tomography

Phase 1

Completed

• Conditions: Heart Failure, Systolic

• Registration Number: NCT03122769
• Lead Sponsor: Henrik Wiggers

Brief Summary

The purpose of the study is to evaluate if metformin is taken up into the failing myocardium. Recent experimental and epidemiological studies have shown beneficial effects of metformin on heart failure. It is unknown whether this effect is direct or indirect.

The aim of the study is to investigate if metformin is taken up in heart failure using a novel 11C-metformin tracer and positron emission tomography (PET).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-04-18
• Study First Submitted QC: 2017-04-18
• Study First Posted: 2017-04-21
• Study Start: 2017-12-01
• Status Verified: 2018-04
• Primary Completion: 2018-04-10
• Study Completion: 2018-04-10
• Last Update Submitted: 2018-04-19
• Last Update Posted: 2018-04-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

• Patients with chronic heart failure, Left Ventricular Ejection Fraction <45%
• New York Heart Association (NYHA) class I, II, III
• Relatively preserved renal function (eGFR > 30 ml/min)
• Ability to understand the written patient information and to give informed consent
• Negative p-HCG for women of childbearing potential

Exclusion Criteria

• Known allergy to metformin
• Age < 18 years
• Current abuse of alcohol or drugs

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Metformin uptake in the failing myocardium	12 months	Cardiac uptake is evaluated through analysis of acquired PET-images.

Trial Locations

Locations (1)

Aarhus University Hospital, Department of Cardiology, Palle Juul-Jensens Boulevard 99; 🇩🇰 Aarhus N, Denmark